This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817…

Focal Onset Seizures

~Estimated

~$10 – $8,750

Supernus Pharmaceuticals, Inc.NCT06798896

Phase 3

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of…

Focal Onset Seizures

~Estimated

~$10 – $8,750

Xenon Pharmaceuticals Inc.NCT05716100

Phase 2

An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures

This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.

Focal Onset Seizures

~Estimated

~$10 – $8,750

Supernus Pharmaceuticals, Inc.NCT07141329